The estimated Net Worth of Timothy Petersen is at least $93.2 Millón dollars as of 19 October 2018. Timothy Petersen owns over 200,000 units of SI-BONE Inc stock worth over $25,561,143 and over the last 10 years Timothy sold SIBN stock worth over $67,590,730.
Timothy has made over 17 trades of the SI-BONE Inc stock since 2014, according to the Form 4 filled with the SEC. Most recently Timothy bought 200,000 units of SIBN stock worth $3,000,000 on 19 October 2018.
The largest trade Timothy's ever made was selling 601,000 units of SI-BONE Inc stock on 28 January 2015 worth over $19,201,950. On average, Timothy trades about 133,477 units every 83 days since 2014. As of 19 October 2018 Timothy still owns at least 1,695,036 units of SI-BONE Inc stock.
You can see the complete history of Timothy Petersen stock trades at the bottom of the page.
Timothy's mailing address filed with the SEC is 303 DETROIT STREET, SUITE 301, , ANN ARBOR, MI, 48104.
Over the last 6 years, insiders at SI-BONE Inc have traded over $114,943,926 worth of SI-BONE Inc stock and bought 1,250,000 units worth $18,750,000 . The most active insiders traders include David P Bonita, Advisors Llc Orbi Med Capit... y John Gordon Freund. On average, SI-BONE Inc executives and independent directors trade stock every 8 days with the average trade being worth of $401,535. The most recent stock trade was executed by Anshul Maheshwari on 3 September 2024, trading 1,414 units of SIBN stock currently worth $23,119.
si-bone® is focused on helping patients in one of the most under-served, under-diagnosed, and under-treated areas in orthopedics, the sacroiliac (si) joint. si-bone developed an innovative, patented implant to fuse the si joint. the ifuse implant system® provides a less invasive alternative to traditional sacroiliac (si) joint fusion surgery and has been used in over 25,000 procedures to date. the company is managed by an experienced team of executives from kyphon, medtronic, inbone, saint francis and several start up orthopedic and spine companies. the ifuse implant system is intended for sacroiliac fusion for conditions including sacroiliac joint dysfunction that is a direct result of sacroiliac joint disruption and degenerative sacroiliitis. this includes conditions whose symptoms began during pregnancy or in the peripartum period and have persisted postpartum for more than 6 months. there are potential risks associated with the ifuse implant system. it may not be appropriate for al
SI-BONE Inc executives and other stock owners filed with the SEC include: